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related to pediatric HSCT/oncology and to evaluate their
expectations in terms of training and education.
Methodology: An online questionnaire was set up (Qual-
trics) to evaluate knowledge and need for training. It con-
sisted of a general part, a part evaluating theoretical
knowledge on HSCT/pediatric oncology and some examples
to gain insight in the way they give pharmaceutical advice.
The ﬁnal part involved issues on past/present education.
Results: In total, 223 responses from 156 CP and 67 ST were
obtained. Of them, 26.3% (CP) and 11.9% (ST) were involved in
providing medication to this population. Only 34.0% (CP) and
44.0% (ST) gave correct answers to general questions. In total,
39.3% (CP and ST) had no idea how to handle this question or
to give advice (47.5%).
In total, 98.7% (CP) and 97.0% (ST) found the knowledge
they gained at the university insufﬁcient for their profes-
sional practice. None of CP and 4.5% (ST) had lessons on this
issue during their basic curriculum. Nevertheless, 68.6% (CP)
and 79.1% (ST) found it necessary to implement this subject
in the university curriculum. Finally, 91.0% (CP) and 89.6%
(ST) were voluntary to follow post-university education on
this subject (evening session or e-learning module).
Conclusion: Although the role of CP in pediatric HSCT/
oncology has been established, the results of this study show
a lack of knowledge and need for training. Both CP and ST are
interested in this subject and, apart from implementation in
the basic curriculum, they prefer evening sessions or e-
learning training to optimize their pharmaceutical care.537
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Introduction: Chemotherapy errors in the hematopoietic
stem cell transplant (HSCT) setting cause signiﬁcant
non-hematologic morbidity and mortality. The existing
“shame and blame” culture prevents error reporting, pro-
motes “work around” solutions, and fails to identify root
causes. The University of Virginia Health System imple-
mented LEAN principles and the A3 problem solving tool to
identify problems related to patient and employee safety,
and focus on system issues versus human error in order to
standardize work, eliminate waste and increases efﬁciency
of healthcare delivery.
Objective: To report the A3 analysis of a chemotherapy error
in which a HSCT patient scheduled for reduced intensity
ﬂudarabine/busulfan conditioning chemotherapy received
10 busulfan doses instead of the 8 intended.
Methods: Amultidisciplinary teamwas assembled including
a process coach. The A3 rigor was applied to: 1) Directly
observe the disciplines who provided the care then
visually illustrate the algorithm of the current state for the
ordering, veriﬁcation and administration of chemotherapy;
2) Identify the problem statement and associated violations
in Rules of Use (ﬁgure 1); 3) Identify the goal/target state;
4) Analyze to root cause by asking cascading “why”
questions starting with the problem statement; 5) Identify/
implement countermeasures to the root cause; 6) Measure
outcomes.
Results: The current condition is illustrated in ﬁgure 2.
Storm clouds indicate violations in Rules of Use. The
problem statement was “a patient received 2 unintended
doses of chemotherapy” and the identiﬁed root cause was
the use of a drug record not conﬁgured to the standard
treatment plan leading to the omission of therapy duration
(activity rule violation). Other contributing causes were
non-standard work and unclear communication regardings in Use
Figure 2. Current condition
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achieve the target condition that “patients will always
receive the intended duration of chemotherapy,” the
following countermeasures were proposed: 1) Conﬁgure a
hard stop in the chemotherapy drug records to add dura-
tion for safe use outside of the standard treatment plan
template; 2) Standardize communication so all providers
are aware of the intended treatment plan; 3) Create reports
in the electronic medical record to standardize the work
involved in the process of prescribing, veriﬁcation and
administering chemotherapy.
Conclusions: The A3method allowed for rapid identiﬁcation
of the root cause and implementation of target workﬂow.
Countermeasures have been identiﬁed and are currently
being implemented. Implementation of the identiﬁed
countermeasures will be assessed to ensure all chemo-
therapy orders have appropriate durations, including
appropriate follow up adjustments to the process as needed.538
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Background: Patients undergoing allogeneic hematopoietic
stem cell transplantation (HSCT) are at risk for infection
from numerous opportunistic infections. Pneumocystis jir-
oveci pneumonia (PJP) is a potentially life-threatening
infection, which can manifest in immunocompromised in-
dividuals. The risk of PJP after allogeneic hematopoietic
stem cell transplantation (HCT) is approximately ﬁve to
15 percent in the absence of prophylaxis. Current prophy-
laxis for PJP can include trimethoprim-sulfamethoxazole
(TMP-SMX), dapsone, atovaquone and inhaled pentam-
adine (PEN), often with varying breakthrough rates. Issueswith nebulized pentamidine treatment may include poor
adherence to the regimen, coordination with medication
administration and reimbursement. The use of intravenous
(IV) PEN for PJP prophylaxis has been associated with
minimal breakthrough rates in pediatric patients. However,
no large studies have hitherto evaluated the efﬁcacy of IV
PEN for PJP prophylaxis in adult allogeneic HSCT patients.
Methods: We performed a single-institution retrospective
review of electronic medical records of patients who un-
derwent allogeneic HSCT between 1 January 2001 and 1
May 2013, and who had received at least one dose of IV PEN.
Data collected included patient demographics, diagnosis,
previous chemotherapy, pre-transplant conditioning
regimen, other medications, microbiology test results, and
clinical outcomes.
Results: One hundred thirteen (113) patients who under-
went 124 allogeneic HSCTs were included in the study. The
median number of PEN doses administered per patient was 3
(range, 1-23). Seventy-four of the patients (65%) received IV
PEN as primary PJP prophylaxis; thirty-nine (35%) had IV PEN
as second-line prophylaxis post-transplant, most switching
from oral TMP-SMX because of intolerance to that medica-
tion. Side effects of IV PEN administrationwere minimal; one
patient had transient shortness of breath after infusion. No
patients who had received IV pentamidine developed PJP
infection. No cases of PJP were observed in the 124 allogeneic
HSCT recipients who received PJP prophylaxis with agents
other than IV PEN.
Conclusion: This retrospective study showed that IV PEN is
effective in prevention of PJP, with no cases of PJP break-
through and minimal side effects during administration.
Intravenous PEN should be considered as an alternative to
PJP prophylaxis with TMP-SMX, and in situations where
other agents may be contraindicated. Our ﬁndings support
prospective studies of IV PEN in adult allogeneic HSCT
recipients.539
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Background: National guidelines recommend antimicro-
bial prophylaxis for allogeneic hematopoietic stem cell
transplant (HCT) patients during the pre-engraftment
period due to increased infection risk. Fluoroquinolones
have demonstrated lower rates of bacteremia and inci-
dence of neutropenic fever, but there is limited evidence
for the use of alternative antibacterials, such as cefpo-
doxime, for patients with an allergy or adverse effect to
ﬂuoroquinolones.
Methods: This is a single-center, retrospective chart re-
view of adult patients who received an allogeneic HCT
from matched related or matched unrelated donors and
received antibacterial prophylaxis with levoﬂoxacin or
cefpodoxime from January 1, 2011 to September 1, 2013.
The primary objective of this study is to compare the rates
of antibiotic prophylaxis failure between levoﬂoxacin and
